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ike everyone of us, I am deeply concerned about HIV/AIDS and its
devastating impact on the life of million of people worldwide.
Despite the financialcommitmentofthe internationalcommunity,
the epidemicisfar from being under controland continuesto pose
a great challenge to economic and social development. The epidemic is
increasinglyaffecting women and girlsthuscreating a secondarymajor impact
of HIV/AIDS – orphaning of children. Women and children must be the focus
of renewed efforts by the international community to respond to HIV/AIDS.   
Where are we in our global efforts to confront HIV/AIDS? 
For the first time, there is a decline in the number of new infections among
urban populations in the developing world. The number of patients treated
with lifesaving anti-retroviral therapies has increased 8 times in the last three
years. And yet still only one out of six Africans in need of this therapy actually
receives it.
The fight against HIV/AIDS is a real cause for Europe. The correct policy frame-
workhasbeen putin place bythe European Communityand itsMember States
in the last few years. They have worked together to develop a Programme for
Action to confront HIV/AIDS, malaria and tuberculosis through external assis-
tance, mobilize funding and develop effective ways to provide  assistance to
our partners to raise awareness and deliver prevention, treatment, care and
support to the populations affected by the pandemics.     
In order to fulfilitscommitments, the European Communityhasallocated, over
the years, an increasing amount of financial resources to confront HIV/AIDS. In
the last 4 years (2003 – 2006) an overall amount of over €1.1 billion has been
allocated to partner countries through a wide array of financial instruments
(with an average of €280 million per year), which represents an almost four-
fold increase from the annual average in the period 1994-2002.
The European Union is strongly committed to scale up its efforts and to pro-
vide the necessary support to reverse the spread of HIV/AIDS and to achieve
L
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the other Millennium Development Goals. To this end, the European
Community is taking further steps to strengthen the European response in the
attempt to raise the level of funding for HIV/AIDS, achieve a higher degree of
coordination with its Member States and further improve the effectiveness of
its development assistance.
In recognition of the strong needs of Sub-Saharan countries in dealing with
HIV/AIDS and other communicable diseases, Europe has committed itself in
2005, through the adoption of the European Strategy for Africa, to increase its
efforts to deliver decent health care through confronting the health providers’
crisis, building capacity at country level and health-related research.  
In the years ahead, the European Community will continue to work through
country and regional programmes. It will also continue to work at global level
through innovative and effective partnerships where Europe is playing a piv-
otal role such as the Global Fund to fight HIV/AIDS, Tuberculosis and Malaria
(GFATM), the International AIDS Vaccine Initiative (IAVI), the International
Partnership on Microbicides (IPM) and others. 
We attach greatimportance to our stakeholdersand willkeep working in strong
co-operation with all of them, from both the public and private sector. The
efforts of the public sector alone are not sufficient to provide an appropriate
response to HIV/AIDS. To achieve good results in this endeavour the strong
support of private business is also particularly needed. 
Putting HIV/AIDSand the other communicable diseasesunder controlisa chal-
lenging undertaking. The European Community is fully committed to making a
major contribution to the success of this undertaking in order to save million
of people’s lives.
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The state 
of the epidemics
HIV/AIDS
AIDS, which has killed 25 million people over the last 25 years, continues to
be one of the most destructive epidemics. Despite the recently documented
decrease in the rate of infection in some countries, the overall number of peo-
ple living with HIV/AIDScontinues to grow worldwide with the exception of the
Caribbean. By the end of 2005, 40.3 million people were estimated to be liv-
ing with the disease, with almost 5 million people infected in that year alone.
In the same year, 3.1 million people died of HIV/AIDS, half a million of which
were children(
1).
Sub-Saharan Africa continues to face the fastest spread of the infection, most
rapid growth in the number of people living with the infection and the highest
HIV/AIDS mortality rate. In 2005 alone, 3.2 million Africans became infected
with HIV, bringing the total number of people living with HIV in Sub-Saharan to
staggering 25.8 million. An estimated 2.4 million Africans died of HIV-related
illnesses such as tuberculosis and opportunistic infections during the same
year.
The spread of HIV/AIDS continues to grow also in other regions. Recent devel-
opments in Eastern Europe and Central Asia are of great concern. Since 2003
the number of people living with HIVin this part of the world grew by one quar-
ter and reached the levelof1.6 million while the number ofAIDSrelated deaths
almost doubled. In East Asia the number of people living with HIV increased
by one fifth over the same period.
(1) AIDS epidemic update: Special Report on HIV Prevention. Geneva UNAIDS/WHO, 2005.
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The HIV/AIDSepidemicisincreasinglyaffecting young women. Whereasin 1985
women formed 38 per cent of all adults living with HIV/AIDS, today the overall
number of men and women living with the infection is almost equal. The dis-
proportionate spread of the infection among women is most striking in Sub-
Saharan Africa where 3 outof5 people living with the infection are women. This
makesAfrica home to 77 percentofallwomen with HIV. The proportionsare sim-
ilar in the Caribbean, the second most affected region of the world. Elsewhere,
HIV prevalence among female population is lower but follows a rising trend(
2).
Prevention, treatment and care efforts of the international community to con-
frontHIV/AIDShave showed some positive results. Prevention effortsand care
have contributed to a decrease in HIV incidence among men having sex with
men in several Western countries, among young people in Uganda, sex work-
ers in Thailand and Cambodia and among injecting drug users in Brazil. There
is also evidence that some prevention programmes are producing positive
results by reducing the incidence rate in some countries such as Kenya,
Zimbabwe and the urban section of Haiti.
Similarly, reduction in prices of the most expensive pharmaceutical products
and the provision of treatment to those in need has resulted in substantial
increase in access to anti-retroviral treatment (ART) around the world. This
increase has been most dramatic in Sub-Saharan Africa where 1 out of 6 peo-
ple in need have access to anti-retroviral therapy. Yet, this progress is visible
only in a handful of countries such as Botswana and Uganda, with coverage
reaching 50 per cent or higher, or in South Africa which accounts for one quar-
ter ofallpeople receiving antiretroviraltherapyin Africa. Elsewhere on the con-
tinent, access to treatment continues to be severally limited. Outside of Africa,
most progress has been made in South America with remarkable 80 per cent
coverage rates in Argentina, Brazil, Chile and Cuba and in South East Asia
where Thailand has been the main driving force behind such progress(
3).
(2) Women and HIV/AIDS: Confronting the Crisis. Geneva UNAIDS/UNFPA/UNIFEM, 2004.
(3) Progress on Global Access to HIV Antiretroviral Therapy: A Report on “3 by 5” and Beyond. 
Geneva UNAIDS/WHO, 2006.
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Malaria
Despite the fact that malaria is both a curable and a preventable disease, it
continues to cause annually the death of more than 1 million people, mostly
in Sub-Saharan Africa. Over 3 billion people around the world, particularly
those living in the poorest countries are at risk of contracting the infection.
Rural communities – in particular children under five years old and pregnant
women – are worstaffected astheyhave reduced accessto effective treatment
and prevention services and commodities. 
Malaria is a contributing factor to low birth weight, chronic anaemia, epilepsy,
learning difficulties and weakened immunity which itself causes another 2 mil-
lion premature deaths among vulnerable groups(
4).
Besides premature deaths, malaria causes more than 300 million acute ill-
nesses and is one of the leading causes of school and work absences, under-
mining education and development.  Annualeconomicgrowth in countrieswith
high malaria transmission has historically been lower than in countries with-
out malaria.
Tuberculosis
One-third ofthe world’spopulation isinfected with tuberculosis, although only
5 – 10 per centofthose who are infected buthave otherwise a healthyimmune
system become sick or infectious during the course of their life. People whose
immune system has been undermined by HIV are much more likely to develop
tuberculosis, as HIVincreases the likelihood of a new tuberculosis infection or
promotes progression of latent tuberculosis infection to an active disease. It is
estimated that one third of all people living with HIV/AIDS are co-infected with
tuberculosis and that tuberculosis is the leading cause of death among HIV-
infected people today. In 2004, the disease caused 1.7 million deaths around
(4) 2005 World Malaria Report. Geneva WHO/UNICEF, 2006.
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the world with most of them in developing countries of Africa, South East Asia
and Western Pacific(
5). 
Tuberculosis primarily affects the poorest groups of population. Crowding,
poor hygiene and malnutrition are important risk factors, all closely linked to
poverty. Access to prompt case detection, diagnostics and treatment is the
main tool for controlling transmission and reducing the spread of the disease.
The most vulnerable groups continue to face a reduced access to health serv-
ices as well as effective diagnosis and treatment.
The internationally recommended approach to tuberculosis control is DOTS-
Directly Observed Treatment Short Course, an inexpensive strategy developed
by the World Health Organization (WHO) that could prevent millions of tuber-
culosiscasesand deathsover the coming decade. The DOTSstrategyfor tuber-
culosiscontrolconsistsoffive keyelements: politicalcommitment, microscopy
services, drug supplies, surveillance and monitoring systems, and use ofhighly
efficaciousregimeswith directobservation oftreatment(
6).  In 2003, 182 coun-
tries were implementing DOTS strategy, covering thus almost 80 per cent of
world’s population. More than 17 million tuberculosis patients and almost
9million smear positive patients have received treatment under the DOTSpro-
grammes between 1995 and 2003.
(5) WHO Tuberculosis Fact Sheet, No. 104, 2006. 
(6) 2005 Global Tuberculosis Control: Surveillance, Planning, Financing, Geneva, WHO, 2006. 
o cueSD U 8/07/06 :03 age 8The EU response to the three diseases  | 9
The EU response  
to the three 
diseases
The European Union hasbeen atthe forefrontofconfronting HIV/AIDS, malaria
and tuberculosis in developing countries. The European Community and its
member Stateshave worked together to design a comprehensive policyframe-
work, mobilize funding and develop effective ways to provide assistance to
developing countries in their effort to deliver prevention, treatment and care
services for their populations affected by the three pandemics. These efforts
have been complemented by contributions from international donors, private
foundations, civil society organizations and non-governmental organizations.
As a result, the response to the three diseases has been significantly acceler-
ated in the last several years, although further major steps have to be taken to
put the three diseases under control.
In general, political will has increased over the last several years and so have
advocacy efforts of civil society groups worldwide. International funding avail-
able to confront HIV/AIDS, malaria and tuberculosis has also increased and
efforts to reach universal access to prevention, treatment and care have been
intensified. Despite that, the challenges that the three diseases pose are still
enormous. HIV/AIDS, malaria and tuberculosis can be prevented and treated,
but developing countries need to adopt appropriate strategies with a compre-
hensive policymixofprevention, treatmentand care. Manyhealth systemsare
showing signs of weak infrastructures and with limited human resources.
Provision of treatment requires substantive and predictable funding. More
research efforts to develop new prevention, care and treatment methods are
needed. Moreover, there is still a strong need for financial resources to fulfil
developing countries needs and halt the spread of the three diseases. 
Three of the eight Millennium Development Goals (MDGs) relate specifically to
health with one focused exclusively on HIV/AIDS, malaria and other diseases.
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Progress towards these MDGs has been particularly slow in Africa. With dete-
riorating life expectancy in a number of sub-Saharan African countries, and
unacceptable levelsofmaternaland childhood mortality, the health MDGsrep-
resent a particular challenge in this part of the world.
The European Community is contributing to achieving the health MDGs both
through country programmes and through support of global initiatives. The
overall commitment of the European Union to the Millennium Development
Goalsremainshigh, with the Union collectivelyfinancing approximately50 per
cent of global external aid in the area of HIV/AIDS, health and population
through its vast presence in developing countries.
In 2005 the European Union has agreed to increase Official Development
Assistance (ODA) resources, with member Statesexpected to allocate 0.51 per
cent of their GNI to development assistance by 2010 and at least 0.7 per cent
of GNI by 2015. The increase in the level of development assistance has been
underpinned by important steps towards more coordination of the EU devel-
opment policies. In December 2005, the European Union adopted a new
European development policy framework – the European Consensus on
Development – agreeing on objectives, policies and principles for both the
European Communityand itsMember States. In addition, a new EU strategyfor
Africa, where progress towards the achievement of health Millennium
Development Goals (MDGs) remains very limited, was adopted at the end of
2005. Relevant measures were taken by the European Community and its
Member States aimed at the increasing aid effectiveness and achieving better
results for each Euro spent. 
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Implementing  
a comprehensive policy   
framework
The European Commission’sstrategyin the field ofthe three diseaseswasout-
lined in the The EC Programme for Action (2001 – 2006) to confront HIV/AIDS,
malaria and tuberculosis in the context of poverty reduction. The policy frame-
workadopted in 2000 was designed to pursue a coherent and comprehensive
approach to the three diseases. The Programme for Action argued thatsuccess
in confronting the three diseases could not be achieved without addressing
simultaneously prevention, treatment and care both at the country and global
level. The policyframeworkemphasized the linkbetween the three pandemics
and poverty, and stressed the need for genuine country ownership of strate-
gies dealing with HIV/AIDS, malaria and tuberculosis within the framework of
poverty reduction. The main objective of the Programme for Action was to pro-
vide guidance in a way that would lead to higher impact of EC interventions,
wider access to treatment in developing countries and more research and
development of tools for prevention and treatment. 
Although the European Commission began to shape its policy as early as in
1987, the adoption of the ECProgramme for Action (2001 – 2006) led to a sig-
nificantlyincreased cooperation acrossdifferentpolicyareas. For the firsttime,
policies in areas such as trade, research and development were being “pulled
together” in an effort to confront the three diseases. This had a major impact
on the magnitude and visibility of the European Community response to the
pandemics. Particular success was achieved in the following areas:
• Four-fold overall increase in ECassistance to confront the three diseases;
• Reduction in prices of key pharmaceuticals, most notably anti-retrovirals
(ARVs) by up to 98 per cent;
• Strong European voice and leadership in international forums including
WHO, WTO, G8 and the creation of the Global Fund to fight AIDS, Tuber-
culosis and Malaria.
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The success in key areas outlined by the Programme for Action confirmed that
the European Union had setitselfcorrectpolicypriorities. Yet, the ongoing chal-
lenge of putting the three diseases under control has led to the need to widen
the scope of the existing policy further.
Widening the scope of policy framework
Towards the end of 2004, based on the results of a wide stakeholder consul-
tation with partner countries, EU Member States, civil society, private sector,
the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), the World
Bank, UN agencies and other institutions, the European Community adopted
a  Coherent European Policy Framework for External Action to Confront
HIV/AIDS, Malaria and Tuberculosis(
7). Member Stateswelcomed thisnew pol-
icy framework and requested the European Community to present a
Programme for Action by April 2005. Due to the re-emerging epidemic in
Europe and its neighbouring countries, the EC also highlighted the need for
immediate action through a separate strategy(
8) proposing a set of concrete
actions in those regions. 
The new policy framework has outlined the need to respond to the following
challenges:
• Increasing and rapid spreading ofthe diseases(especiallyHIV/AIDSand
tuberculosis) in all regions despite remarkable efforts and increased
resources;
• Large burden ofHIV/AIDSand malaria on Sub-Saharan African countries;
• Need to maintain a comprehensive policy mix of prevention, treatment
and care given the growing focus on HIV/AIDS treatment;
• Considerable financial gap in terms of resources available for the three
diseases;
• Reaching the most affected countries and the most vulnerable groups of
the population such as women, children/orphans and people living with
HIV/AIDS and tuberculosis who have to face stigma and discrimination;
(7) “A Coherent European Policy Framework for External Action to Confront HIV/AIDS, Malaria and
Tuberculosis (tuberculosis)” (COM(2004 726).
(8) Staff Working Paper adopted by the Commission on 8 September 2004.
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• Strong political leadership and commitment in partner countries to
develop and support effective policies and mobilize resources;
• Deeper involvementofthe private sector in supplying financialresources
and appropriate skills;
In order to respond to these challenges, the European Community adopted in
2005 “A European Programme for Action to Confront HIV/AIDS, Malaria and
Tuberculosis through External Action (2007-2011)” which suggests for the
first time collective EU (EC and EU Member States) action to support country-
lead programmes confronting the three diseases as well as action at global
level in areas where the EU can add value. In geographic terms, the Pro-
gramme for Action covers both developing and middle-income countries.
At country level, the Programme for Action proposes to improve political and
policydialogue on severaltopics, including human rights-related issues, needs
of vulnerable groups of the population and issues around stigma and discrim-
ination. It also puts emphasis on monitoring and data collection; capacity
building in the areasofhuman resources, clinicalresearch, pharmaceuticaland
procurement policy; the need to create synergies with programmes promoting
sexual and reproductive health and rights; human security issues. The Pro-
gramme for Action also arguesfor increased financialresourcesto confrontthe
three diseases and a series of highly cost-effective interventions likely to yield
rapid results.
At global level, the Programme for Action proposes action to strengthen
regional networks and cooperation, to promote affordable and safe pharma-
ceutical products, to strengthen regulatory capacity of partner countries in col-
laboration with WHO and the European Medicines Agency (EMEA), to address
the human resource crisis for health providers, and to support research and
development of new tools and interventions. In addition, it calls for a strong
partnership with key organisations and initiatives, including the Global Fund
to Fight AIDS, Tuberculosis and Malaria and for a close consultation with key
players through the EC Stakeholder Forum.
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Areas of intervention 
through the Programme for Action
Increasing access to medicines
At the 11
th International AIDS Conference in Vancouver in 1996, researchers reported a
groundbreaking discoveryleading to promising resultsin treating people with HIV/AIDS.
Those results were, however overshadowed by the cost of the medicines newly
patented. By 1999, treatment for people with HIV/AIDS in Europe and the US became
standard butbecause ofthe high cost(€10,000 - €20,000/person/year) the same medi-
cines would not be affordable for a long time for the most affected populations in the
developing world where health spending per capita is very low.
In September 2000, the Commission organised a Round Table with the President of the
European Commission, 7 Commissioners, 7 CEO's from pharmaceutical industry, MSF
and ACTUP in the presence of the Executive Directors of UNAIDS and WHO. The Round
Table agreed on a concept to respect intellectual property rights for medicines, while
agreeing on competition from generic producers, lowering tariffs and taxes where
needed and agreeing on tiered pricing of medicines to provide affordable prices for the
developing world. At the Round Table, the Indian manufacturer Cipla announced, they
would make ARV available at €350/person/year – a fraction of the original price of
€10,000/person/year.
The European Commission agreed to protect against re-importation of tiered priced
products to European countries through a regulation. The EC also untied procurement
of aid for medicine and agreed to review the TRIPs agreements to allow countries not
producing medicines to import products from other countries under compulsory licens-
ing agreements.
Even though tiered pricing schemes have been put in place by several research based
pharma manufacturers a lot remains to be done on the part of the industry to meet
needs for lowest possible prices with respect to both existing and new products.
In addition, developing countriesneed capacitiesto produce and purchase cheap medi-
cines regardless of whether they are under patents or not. Under the 2001 WTO Doha
Declaration on the relationship between public health and the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPs), developing countries gain sub-
stantial freedom in determining their national health policies while protecting
intellectual property rights. In addition, least developed countries (LDCs) are exempted
from putting national patent legislation in effect until 2016, which means they are free
to produce any medicine regardless of its patent status until then.
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Improving national regulatory frameworks 
in developing countries
The ECisassisting developing countriesto improve their regulatoryframeworksto facili-
tate marketing approvals of pharmaceuticals. A key achievement in this field has been
the recent amendment of the EU pharmaceutical regulation, which allows for the
European Medicines Agency (EMEA), in cooperation with the WHO, to provide scientific
opinions on medical products for human use exclusively outside of the EU. This could
facilitate the procedure for developing countries and encourage exporters to reach out
for new markets.  
Strengthening of pharmaceutical policies
Optimal use of key pharmaceutical products in confronting HIV/AIDS, malaria and
tuberculosis is essential to maximize the impact of interventions. The EC has allocated
€25 million for support through the WHO to implement a programme enhancing capac-
ity of developing countries to develop, implement and monitor national drug policies,
and negotiate and monitor internationaltrade agreementson pharmaceuticalproducts.
Part of the funding has been used for the WHO prequalification programme that
assesses the quality, safety and efficacy of drugs submitted by drug manufactures. The
overall objective of the programme is to improve the potential of essential drugs in
response to the fact that that for millions of people – particularly poor and disadvan-
taged – drugs are still unavailable, unaffordable, unsafe or improperly used. 
Support to the development of national manufacturing capacities
The EC supports initiatives promoting local production of pharmaceutical products for
the prevention and treatment of HIV/AIDS, malaria and tuberculosis. As demonstrated
byan ECsupported feasibilitystudy, there isa clear potentialfor localproduction ofcon-
doms in many developing countries. Similar opportunities exist for other products such
as long-lasting insecticide treated nets, antiretroviral drugs, anti-malarial combination
protocols and anti-tuberculosis pharmaceuticals.
Responding to the shortage of health workers 
to deliver essential services
The lack of doctors and nurses in many developing countries and especially in Africa
has become a significant barrier to progress towards the Millennium Development
Goals, slowing effortsto reduce maternal, infantand child mortalityand tackle diseases
like HIV/AIDS, tuberculosisand malaria. The European Commission iscommitted to help
improve human resources planning and management in the countries most affected by
the outflow of health service providers while helping to decrease brain drain of health
staff towards industrialized countries. As a first step, the Council adopted in December
2005 a strategy to combat the shortage of health workers in developing countries and
the EC is convening a special working group to consider an European Code of Conduct
for Ethical recruitment and identify coordinated actions to support countries build their
human resource capacity and strengthen regional cooperation in this area. The priority
will be to strengthen national capacity to train, support and retain an expanded and
more effective health workforce.
o cueSD U 8/07/06 :03 age 516 | Mobilizing funding
Mobilizing 
funding
The European Community’s commitment to develop and implement effective
policies has been underpinned by its effort to mobilize sufficient funding that
would help partner countries to confront the three diseases. Since its early
response, the European Community has been steadily increasing its financial
support in these areas and has worked as an important catalyst in pooling
resources of the EU Member States and other donor partners.
Asin the past, between 2003 and 2006, the bulkofthe European Community’s
assistance to partner countries in the area of health and communicable dis-
eases was channelled through country and regional indicative programmes,
usually covering a period of four to five years. These programmes are devel-
oped as part of the country and regional strategy papers jointly agreed by
nationalauthorities, the European Communityand EU Member States. In addi-
tion to country and regional funding, the European Community provided sub-
stantial support in the same areas through thematic funding, mainly thematic
budget lines, NGO co-financing budget line and Research funding. 
In the four-year period (2003-2006), the amount of resources specifically allo-
cated to confront the HIV/AIDS, malaria and tuberculosis has drastically
increased compared to the past. The EC has programmed an annual average
of €259 million to confront the three diseases, which represents a four-fold
increase from the annualaverage of€59.3 million allocated between 1994 and
2002. Additionalfunding hasbeen targeted atthe supportofhealth and social
services through general or sector budget support.
Most of the thematic funding to confront the three epidemics was channelled
through the budget line for poverty-related diseases (€351 million for the
period 2003-2006) which represent an appropriate financial instrument to
implementinnovative initiativesand targeted actionsincluded in the European
Programme for Action. The added value of thematic funding was to allow for
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flexibility and additional impact beyond geographic resources. While geo-
graphicprogrammeswere able to addresshealth interventionsatnationaland
regional level, the poverty-related budget line was able to ensure impact and
visibility of EU action at global level, including through the Global Fund to fight
HIV/AIDS, Tuberculosis and Malaria (GFATM) and several other partnerships.
In addition to the support to the Global Fund to fight HIV/AIDS, Tuberculosis
and Malaria, thematic funding has been allocated to NGOs, research institu-
tions and other organizations in partner countries, international organizations
including the United Nations agencies in the area of operational research,
advocacy and capacity building. Moreover, the European Community has
provided financial support to major global events such as the bi-annual
International AIDS Conference (Bangkok 2004, Toronto 2006), the Conference
on Microbicides (Cape Town 2006), and the Eastern European and Central
Asian AIDS Conference (Moscow 2006). 
EC financial commitments / programmed support
to confront HIV/AIDS, tuberculosis and malaria 
(annual average in € million)(
9)
Type of support Annual average Annual average
1994 – 2002 2003 – 2006
Regional Budgets 11.92 56.76
Thematic Budgets 10.10 88.25
Humanitarian Aid 1.60 1.50
NGO co-financing 12.60 12.51
Research 23.10 100.00
TOTAL 59.32 259.02
(9) Second progressreporton the ECProgramme for Action: Accelerated action on HIV/AIDS, malaria
and tuberculosis in the context of poverty reduction; Brussels 2004.
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VI Research framework programme and European 
and Developing Countries Clinical Trial Partnership (EDCTP)
The EC spends increasingly more on research programs targeting HIV/AIDS,
tuberculosis and malaria. In 2002 – 2006 the funding for these three diseases
increased four times reaching a total of €400 million. Half of this amount is
administered by the EC itself and is targeted at the support of highly innova-
tive discovery studies and pre-clinical and early clinical testing of new clinical
interventions to confront HIV/AIDS, malaria and tuberculosis. The other half
together with additional €400 million from EU member states is channelled
through the European and Developing Countries Clinical Trial Partnership
(EDCTP). EDCTP is an independent legal entity, based in The Hague (NL) and
with an African Office in Cape Town (South Africa).
EDCTP activities aim at integrating research activities on the three diseases
conducted by the member States national programmes and accelerating clini-
cal investigation and hence the development and availability of new interven-
tions to fight the three diseases. EDCTP provides primarily grants for advanced
clinical trial testing in order to accelerate the development of new or improved
drugs, vaccinesand microbicidesand to improve the qualityofresearch on the
three diseases in developing countries through capacity building programs,
networking grants and training awards.
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Effective ways 
to provide assistance 
to partner countries
The European Commission has taken important steps to make delivery of aid
more effective. The Communication on financing for development and aid
effectiveness adopted by the European Commission in March 2006 outlines
the strategy to improve the effectiveness of aid, which requires action both at
the level of donors and recipients.
As part of the strategy, the way of providing assistance to confront the three
diseases has undergone an important evolution. While in the early years the
EChasfocused primarilyon supporting projectsdesigned to confrontthe three
diseases, currently the main part of the assistance in the area of health and
communicable diseases is allocated through budget support towards country
indicative programmes.
This approach forms the cornerstone of EC assistance and underlines the
importance the EC assigns to country ownership of integrated development
strategies as the best tools for dealing with HIV/AIDS, malaria and tuberculo-
sis. Confronting the three diseasesrequiresa multi-sectoralapproach and part-
ner countries are best positioned to decide how to best allocate resources to
individual initiatives. Effective, equitable and transparent allocation of donor
resourcesatcountrylevelrequiresthe participation ofrelevantgovernmentand
civil society stakeholders, such as parliament, professional associations and
leading NGOsin the planning and decision-making processover budgetformu-
lation and execution.
In addition to countryand regionalefforts, the European Commission hasmade
a significant effort to develop global partnerships that allow for better cooper-
ation with other donors in an attempt to pool resources. The EC has been an
early supporter of the Global Fund to Fight AIDS, Tuberculosis and Malaria
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established in 2001. Similarly, the EC has developed long-term partner-
ships with key organizations operating in the area of HIV/AIDS, malaria and
tuberculosis.
The EU and the Global Fund to Fight HIV/AIDS, 
Tuberculosis and Malaria
The GlobalFund to FightAIDS, Tuberculosisand Malaria (GFATM)(
10) isa financ-
ing mechanism and globalpartnership established in 2001 aspartofthe inter-
national response to the global emergency caused by the three communicable
diseases.  The GFATM was created to increase resources to fight the three dis-
eases and to direct them to areas of greatest need. The GFATM finances pro-
grammes developed by different stakeholders at country level, through a
specific coordinating mechanism, to scale up national health and poverty
strategies with the objective to reduce infections, illness and death caused by
HIV/AIDS, malaria and tuberculosis. The Global Fund aims at ensuring open-
ness and transparency in its governance and operations. Its 20 voting mem-
bers Board, with 4 non voting members, makes a quite unique example of
governance in a development-related institution. Actively involved in the cre-
ation ofthe GFATM in 2001/2002, the European Commission hasbeen strongly
involved in the governance of the GFATM through the participation in Board
meetings and committee activities. Currently, the EC is holding the vice-chair-
manship of the Board.
Between 2002 and 2006, the European Commission has provided an overall
contribution to the GFATM of €522 million, thus representing one of its major
donors. The increasingly active role of the ECin the GFATM has also had a pos-
itive impacton the wider role ofthe European Union in the Fund. While between
2002 and 2005 Europe has provided in the average 50% of the overall contri-
butions received by the Fund, in 2006 and 2007 the EU will reach a share of
66% of total resources.
(10) www.theglobalfund.org
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Working in partnership with IAVI and the IPM 
to develop HIV/AIDS vaccine and microbicides
The InternationalAIDSVaccine Initiative (IAVI) and the InternationalPartnership
for Microbicides (IPM) are global partnerships working to speed up the devel-
opment and promotion of new preventative technologies, mainlyvaccines and
microbicides. They both focus on mobilising support through advocacy and
education, accelerating scientific progress, encouraging industrial participa-
tion in AIDS vaccine and microbicides development, and assuring access to
these tools in developing countries. IAVI and IPM are key partners of the EC,
which is a member of the policy advisory Board of both organisations.
In 2006, the EC has programmed support in the amount of €3 million to IAVI
for vaccine preparedness programmes (ethical criteria, regulatory aspects and
preparedness of communities) and the introduction of phase III trials of an
effective and safe HIV/AIDS vaccine in Eastern Africa. In South Africa, the
European Community is supporting the South African Aids Vaccine Initiative
(SAAVI), in partnership with IAVI with a contribution of €1.3 million to inten-
sify vaccine preparedness.
In 2006, the European Community has programmed financial support to IPM
in the amountof€4.2 million in order to accelerate the developmentand intro-
duction of microbicides. Funding will be used to support a wide number of
activities aimed at developing and delivering safe and effective microbicides,
The intent of the European Community is to increase awareness of and inter-
est in microbicides among developing country policy makers, representatives
ofbilateral, multilateraland technicalagenciesin developing countries, activist
and media organisations and development agencies in Europe.
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The support to microbicides and vaccines of the European Community has
been further strengthened by contributions from its Member States, targeted
at research and development as well as policy and advocacy. Since 2002, five
Member States – the Netherlands, Denmark, Ireland, Sweden and the United
Kingdom have committed almost €20 million to IPM. At the end of 2005,
Denmark, Sweden, Ireland and the United Kingdom made additional commit-
ments to provide more than €25 million to IPM through 2007. A great number
of European Member States provides contributions to programmes managed
by the EDCTP.
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The way forward 
to confront HIV/AIDS,
malaria and tuberculosis
At the end of 2005, the European Community, the European Parliament and
the Council have adopted a new development policy framework, the Euro-
pean Consensus on Development, based on common objectives, policies and
principles.
The new policy framework spells out the commitment to further strengthen
work at country and global level in order to improve peoples’ lives in line with
the Millennium DevelopmentGoals. In order to confrontthe devastating impact
of HIV/AIDS, malaria and tuberculosis, the European Community will develop
a road map for joint actions with its member States at country level. Moreover,
it will focus on a number of key issues such as:
• Link between the fight against HIV/AIDS and the support to sexual
and reproductive health and rights;
• Crisis of health providers in developing countries;
• Fair financing for health and strengthening health systems in order 
to promote better health outcomes;
• Making pharmaceutical products more accessible and affordable 
to the poor.
Recognizing that countries in Africa and especially in Sub-Saharan Africa are
facing a particularly heavy burden in dealing with the three diseases and have
made least progress in achieving the Millennium Development Goals, at the
end of 2005 the European Union has adopted the EU Strategy for Africa:
Towards a Euro-African Pact to Accelerate Africa’ Development. By approving
this strategy, Europe has made a commitment to scale up its efforts to deliver
decent health care through the strengthening of national health systems,
capacity building and health-related research.
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In order to simplify the legislative framework governing the European
Community’s external cooperation activities and to achieve policy objectives
that cannot be fully achieved through country and regional programmes at the
beginning of2006, seven new thematicprogrammes, which willform the back-
bone of EC’s thematic activities as of 2007, were approved. One of these the-
matic programmes – Investing in People – focused on human and social
development, proposes six areas of intervention: good health for all, knowl-
edge and skills, employment and social cohesion, gender equality, children
and youth and culture. In termsofthe three diseases, the thematicprogramme
reinforces the priorities established in the past and takes up new priorities
defined in the European Consensus on Development.
In the years ahead, the European Community will keep its main focus on coun-
try and regional support. Efforts at the global level will be pursued further
through the implementation of thematic activities in the area of the three dis-
eases including the support to the Global Fund to fight HIV/AIDS, Tuberculosis
and Malaria as well as relevant partnerships with UN agencies and other key
stakeholder organizations. 
It is now time to sustain European efforts to confront three epidemics by mak-
ing use ofthe experience developed so far. We have a much greater knowledge
of how to confront effectively the three epidemics. The right policy framework
has been set, and available tools have proved to be effective at least in some
geographicalareas. Whatwe need isa strong politicalwillofallEuropean part-
nersto further accelerate their effortsand make available increased resources. 
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European Commission
Directorate-General for Development
and Relations with African, Caribbean and Pacific States
Post Address
Rue de la Loi 200
B-1049 Brussels
Fax:
+32 2 299 25 25
E-mail: 
DEV-A5-FMB@ec.europa.eu
Internet: 
http://ec.europa.eu/comm/development/
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